Ivonescimab's differentiated PD-1/VEGF design, expanding Phase III pipeline and $2.0B AstraZeneca investment create substantial oncology upside, but the pivotal U.S. approval faces an OS-evidence hurdle and meaningful dilution remains.
Sell-rated reports
287 tickers rated SellTELUS owns valuable Canadian wireless and fibre networks with recovery potential from cost savings and debt reduction, but heavy leverage, declining profitability and uncertain asset monetizations undermine its near-term investment appeal.
Guardant Health could become a major beneficiary of expanding blood-based cancer screening and precision oncology, but its demanding valuation, persistent cash burn, and unproven operating leverage create substantial investment risk.
Peloton's strong cash-flow recovery and improving balance sheet support its turnaround potential, but persistent subscriber losses and shareholder dilution undermine confidence in durable per-share earnings growth.
Consolidated Edison offers highly defensible regulated utility earnings and a reliable dividend history, but demanding valuation, persistent negative free cash flow, and ongoing equity issuance constrain investment attractiveness.
LivaNova benefits from durable cardiac-surgery and neurostimulation franchises with improving earnings and new-product potential, but demanding valuation and substantial legal liabilities constrain its risk-adjusted appeal.
Keurig Dr Pepper combines durable beverage brands and potential separation value, but heavy acquisition financing and uncertain post-separation cash-flow economics constrain the investment case.
Hagerty's differentiated specialty insurance franchise and improving underwriting economics support long-term growth, but elevated valuation multiples and increased claims-risk exposure limit the investment appeal.
Mobileye offers significant long-term opportunities in advanced driving systems and autonomous mobility, but weak pricing trends, uneven revenue growth, and uncertain returns from robotics investments undermine near-term investment confidence.
Alexandria Real Estate Equities offers a potentially deep valuation discount backed by specialized life science properties and substantial liquidity, but persistent vacancy, declining FFO, and asset impairments threaten its recovery.
AeroVironment is an advantaged defense-drone and counter-UAS platform with record backlog and major laser wins, but acquisition dilution, weak free cash flow, recent control failures and a demanding valuation keep risk-reward unattractive.
Grupo Cibest offers a profitable Colombian banking franchise, strong digital reach, and meaningful dividends, but elevated book-value multiples and rising credit provisions weaken its risk-adjusted investment appeal.